NCT06687070 2025-02-26
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Ascentage Pharma Group Inc.
Phase 1 Recruiting
Clinical Trials
7 trialsNCT06434610 2025-01-27
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2 Recruiting
NCT06509971 2024-07-19
A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
West China Second University Hospital
Phase 2 Not yet recruiting
NCT05325229 2022-10-13
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04348032 2022-03-31
APPROVE
ChineseAMS
Phase 2 Unknown
NCT03699449 2021-04-01
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Yonsei University
Phase 2 Unknown
NCT04720807 2021-01-22
Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown